Total
0
Shares
WPD Pharmaceuticals (CSE:WBIO) to attend the 10th congress of the Polish Society of Pediatric Oncology and Hematology
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ProMIS Neurosciences (PMN) to present at the Second Annual Undruggable Leaders Forum, September 15 to 16, 2021
  • Dr. Johanne Kaplan, will be presenting her talk entitled "Selective Targeting of Misfolded Pathogenic Proteins in Neurodegenerative Diseases"
  • Attendees will learn how ProMIS Neurosciences is using a computational modelling platform to generate monoclonal antibodies
  • Registered attendees can view the presentation live during the conference
  • ProMIS Neurosciences, Inc. (PMN) is trading at C$0.20 at 12:42 pm ET

ProMIS Neurosciences, Inc. (PMN) is participating in the Second Annual Undruggable Leaders Forum, a virtual event to be held on September 15-16.

ProMIS Chief Development Officer, Dr. Johanne Kaplan, will be presenting her talk entitled "Selective Targeting of Misfolded Pathogenic Proteins in Neurodegenerative Diseases" on September 16 at 12:40 pm EST in the session "The Next Undruggable Leaders".

Attendees will learn how ProMIS Neurosciences is using a computational modelling platform to generate monoclonal antibodies selectively targeting conformational epitopes on toxic oligomers of proteins implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

Registered attendees can view the presentation live during the conference; a recorded version for attendees will also be available to watch at their convenience.

ProMIS Neurosciences, Inc. is a development-stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD).

Its proprietary target discovery engine is based on the use of two complementary techniques.

It applies its thermodynamic, computational discovery platform -ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

ProMIS Neurosciences, Inc. (PMN) is trading at C$0.20 at 12:42 pm ET.

More From The Market Herald
Leveljump (TSXV:JUMP) to acquire Ontario clinics

" Leveljump (TSXV:JUMP) to acquire Ontario clinics

Leveljump Healthcare (JUMP) is set to acquire three Ontario diagnostic imaging clinics from a private vendor.
CloudMD (TSXV:DOC) announces a change of auditors and new board of director nominees

" CloudMD (TSXV:DOC) announces a change of auditors and new board of director nominees

CloudMD has nominated Duncan Hannay and Karen Adams to the company’s board of directors.
Psyence Group (CSE:PSYG) and Pure Extracts (CSE:PULL) form psychedelics joint venture

" Psyence Group (CSE:PSYG) and Pure Extracts (CSE:PULL) form psychedelics joint venture

Pure Extracts (PULL) and Psyence Group (PSYG) have formed a JV for psychedelic medicinal mushroom extracts.
PharmaDrug (CSE:PHRX) announces meeting with FDA

" PharmaDrug (CSE:PHRX) announces meeting with FDA

PharmaDrug (PHRX) has been granted a pre-investigational new drug meeting with the FDA for its COVID-19 treatment.